Microbiota and Radiotherapy: Unlocking the Potential for Improved Gastrointestinal Cancer Treatment

Area of Science:

• Microbiology
• Oncology
• Gastroenterology

Background:

• Radiotherapy (RT) is a key treatment for gastrointestinal (GI) cancers.
• RT can cause side effects like intestinal inflammation and dysbiosis.
• The gut microbiota influences RT effects on immunity and tissue repair.

Purpose of the Study:

• To explore the role of gut microbiota in modulating RT efficacy and toxicity in GI cancers.
• To investigate microbiota-targeted interventions for improving RT outcomes.
• To understand the impact of intratumoral microbiota on RT response.

Main Methods:

• Review of clinical investigations and advanced RT techniques.
• Analysis of microbiota-targeted interventions (probiotics, prebiotics, fecal microbiota transplantation).
• Examination of the relationship between microbial diversity and patient outcomes.

Main Results:

• Dysbiosis amplifies RT-induced toxicity.
• Microbiota modulation can augment RT efficacy and reduce side effects.
• Increased microbial diversity and specific profiles correlate with patient improvements.
• Stereotactic body radiotherapy combined with microbiota modulation shows promise.

Conclusions:

• Modulating gut and tumor microbiota is crucial for optimizing RT benefits in GI cancers.
• Personalized therapy approaches incorporating microbiota modulation are essential.
• Targeting the microbiota offers a promising strategy to enhance RT outcomes and patient well-being.